Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib vs taxane chemotherapy in FGFR1/3-positive urothelial carcinoma
CTR20180876Phase 3Terminated
- Sponsor
- Bayer
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rogaratinib in transitional cell carcinoma (TCC), sponsored by Bayer. Started Oct 2018; status: terminated.
02
Drugs
rogaratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20180876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180876.